As the competition in cutting-edge drug research and development intensifies, selecting potential novel targets and forging a unique, visionary path can help innovators stand out. Studies have revealed that the HLA-G/LILRBs pathway has a broader impact than CTLA-4 and PD-1/PD-L1 regulated immune cells. The interaction of HLA-G with LILRB1 has been proven to inhibit the function of NK cells, dendritic cells, monocytes/macrophages, T cells, and B cells, therefore aiding tumor escape. Therefore, LILRB and HLA-G may become the next hot immunotherapy targets.
|